<DOC>
	<DOC>NCT01329627</DOC>
	<brief_summary>The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.</brief_summary>
	<brief_title>Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Locally advanced breast cancer diagnosed by guided core biopsy T &gt; 2 cm (any N), or any T and node positive (needle biopsy is required) Nonmetastatic disease assessed by computed tomography and bone scintigraphy Histological grade 2 and Ki67 &gt; 15% or Histological grade 3 or Any triple negative (TN) or Inflammatory breast cancer (IBC) Normal left ventricular ejection fraction (LVEF) HER2negative disease Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast) Clinically significant comorbidities as cardiovascular diseases, chronic obstructive pulmonary disease (COPD), renal or liver failure, psychiatric disorders LVEF value below institutional limits of normal Predominant lobular carcinoma histology Grade 1 tumors Detected or suspicious distant metastasis Neutrophils less than 1,500/µL, platelets less than 100,000/µL, hemoglobin less than 10 g/dL, AST more than 2.5x upper limit of normal (ULN), total bilirubin more than ULN, alkaline phosphatase more than 1.5x ULN Male sex HER2positive breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>